Reconstitution of CXCR3 + CCR6 + Th17.1‐Like T Cells in Response to Ofatumumab Therapy in Patients With Multiple Sclerosis
Annals of Clinical and Translational Neurology · 2025
DOI: 10.1002/acn3.70042 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Shu Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Multiple Sclerosis, Relapsing-Remitting, Receptors, CXCR3, Th17 Cells. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tianjin Public Health Science and Technology Major Project, National Natural Science Foundation of China, Natural Science Foundation of Tianjin City.
Abstract (Originalsprache)
Background and Objectives Ofatumumab, a fully human anti‐CD20 monoclonal antibody, is effective in reducing relapses and disability progression in patients with multiple sclerosis. This study aimed to examine immune profile changes associated with ofatumumab in a prospective cohort of Chinese patients with relapsing–remitting multiple sclerosis (RRMS).
Methods
Seventeen RRMS patients were enrolled in this uncontrolled, prospective, observational cohort study (OMNISCIENCE study) and received regular subcutaneous ofatumumab treatments. Immune cell subsets were analyzed by single‐cell mass cytometry at baseline and 6 months post‐treatment. Peripheral blood monoclonal cells (PBMCs) from a separate cohort of treatment‐naive RRMS patients were used for cytokine analysis through ex vivo flow cytometry.
Results
Following ofatumumab treatment, B cells in peripheral blood remained depleted, with surviving cells predominantly consisting of antibody‐secreting cells and transitional B cells. Increased proportions of NK cells and myeloid cells, particularly HLA‐DR hi intermediate monocytes, were observed, and FOXP3 and CTLA‐4 expression on CD4 + T cells was upregulated. Notably, prior to the subsequent dose of ofatumumab, Th17.1‐like CXCR3 + CCR6 + memory CD4 + and CD8 + T cell clusters increased significantly, with a transient CD20 expression rebound. In vitro experiments further confirmed that ofatumumab reduced these Th17.1 cell subsets and related pro‐inflammatory cytokines.
Discussion
These findings suggest that ofatumumab impacts interactions among pathogenic B cells, T cells, and myeloid cells, with Th17.1 cells emerging as a potential direct target within T cells. Persistent and regular infusions of ofatumumab appear necessary to sustain clinical efficacy. Trial Registration: ClinicalTrials.gov identifier: NCT05414487
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China.
- Department of Neurology, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin, China.
ORCID-Profile: Tian-Xiang Zhang, Fu-Dong Shi, Chao Zhang
Förderung
- Tianjin Public Health Science and Technology Major Project
- National Natural Science Foundation of China
- Natural Science Foundation of Tianjin City
- Natural Science Foundation of Tianjin Municipality
Zitieren
APA
Yang, S., Zhang, T. X., Liu, J., Liu, Z., Zhu, L., Li, Y. Y., Feng, B., Fan, M., Shi, F. D., & Zhang, C. (2025). Reconstitution of CXCR3 + CCR6 + Th17.1‐Like T Cells in Response to Ofatumumab Therapy in Patients With Multiple Sclerosis. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70042
Vancouver
Yang S, Zhang TX, Liu J, Liu Z, Zhu L, Li YY, et al. Reconstitution of CXCR3 + CCR6 + Th17.1‐Like T Cells in Response to Ofatumumab Therapy in Patients With Multiple Sclerosis. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70042
BibTeX
@article{Yang2025,
author = {Yang, Shu and Zhang, Tian-Xiang and Liu, Jia and Liu, Zhirui and Zhu, Lijie and Li, Yan-Yan and Feng, Bin and Fan, Moli and Shi, Fu-Dong and Zhang, Chao},
title = {Reconstitution of CXCR3 + CCR6 + Th17.1‐Like T Cells in Response to Ofatumumab Therapy in Patients With Multiple Sclerosis},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
doi = {10.1002/acn3.70042}
}
EUVIMED